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Factorial designAbstract Context:Microcrystalline cellulose (MCC) is the most widely used excipient for the pro-
duction of pellets but it retards the release of poorly water soluble drugs. Objective: The present
investigation reports incorporation of camphor, cross carmellose sodium (CCS) and spray dried lac-
tose (SDL) into MCC pellets to enhance the dissolution rate of telmisartan.Materials and methods:
A full factorial design (32) was used in the study. Concentration of camphor and CCS was selected
as independent variables whereas percentage porosity and percentage drug release at 60 min were
selected as dependent variables. Pellets were produced by extrusion–spheronization technique
and evaluated for percentage yield, particle size analysis, ﬂow characteristics, percentage porosity,
drug content and in vitro drug release. Contour plots and 3-D surface plots were presented for
graphical expression of the results. Results and discussion: Pellet formulations exhibited acceptable
morphological, ﬂow and mechanical properties. As against to 38.54% drug release after 60 min with
MCC pellets, pellets prepared with optimized formulation, composed of proper combination of
MCC, SDL, camphor and CCS, released 100% drug after 60 min. Conclusion: Our study underlines
the fact that dissolution of telmisartan from MCC pellets can be successfully enhanced by
incorporating water soluble excipient, disintegrant and pore formers.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Telmisartan is angiotensin II receptor antagonist, which is
used in the prevention and treatment of hypertension. The
solubility of telmisartan in aqueous solutions is strongly pH-
dependent, with maximum solubility observed at high and
low pH values. In the physiological pH range its aqueous
solubility is 0.078 mg/ml. Its poor dissolution characteristics
result into variable absorption and suboptimal bioavailability
(Yanzhuo et al., 2010; Masaaki et al., 1998; Kaura et al.,
Table 1 Composition of preliminary batches (P1–P4).
Batches Composition of pellets
Drug (mg) MCC (mg) Spray dried
lactose
Camphor
(mg)
CCS
(mg)
N9 20 280 – – –
N10 20 244 56(20%)
N11 20 220 – 30(10%)
N12 20 244 – – 36(12%)
580 H. Patel et al.2014). Thus, improving the dissolution behaviour of telmisar-
tan is of therapeutic importance (Wienen et al., 2000; Bala and
Sayyad, 2013).
Pellets are small, free-ﬂowing, spherical particulates pre-
pared by the agglomeration of ﬁne powders of drugs and
excipients (Sellassie and Knoch, 2002; Benchawan and
Pornsak, 2013; Gothi et al., 2010). Microcrystalline cellulose
(MCC) is the most widely used excipient for the production
of pellets due to plasticity and cohesiveness of its wet masses
(Kranz et al., 2009; Alvaro et al., 2011a). However, its
applicability is limited particularly in case of poorly water sol-
uble drugs due to its non-disintegration behaviour of the MCC
pellets. This, in turn, decreases the release rate of drugs from
the pellets (Alvaro et al., 2011b; Jorg et al., 2010). This lim-
itation of MCC pellets has been addressed using a variety of
pharmaceutical approaches. They include the use of 40% of
isopropanol/water mixture as a granulating binder (Schroder
and Kleinebudde, 1995), use of pectinic acid (Tho et al.,
2003) and carrageenan (Kranz et al., 2009) instead of MCC
and incorporation of disintegrants into MCC pellets (Alvaro
et al., 2011a). The present research describes enhancement of
dissolution rate of telmisartan from MCC pellets by
incorporating a varied proportion of superdisintegrant (cross-
carmellose sodium, CCS), pore former (camphor) and water
soluble components (spray dried lactose, SDL). To our
knowledge, such an approach has not been investigated for
dissolution-improvement of telmisartan till date.
Factorial design is an efﬁcient tool for estimating the inﬂu-
ence of individual variables and studying their interactions
using minimum number of experiments (Singh and Ahuja,
2002). A full factorial design (32) was used in the present study.
The concentrations of camphor and crosscarmellose sodium
(CCS) were selected as independent variables whereas; percent-
age porosity and percentage drug release at 60 min were
selected as dependent variables in the design. Pellets were pre-
pared using extrusion–spheronization method and evaluated
for percentage yield, particle size analysis, ﬂow characteristics,
percentage porosity, drug content and in vitro drug release.
Contour plots and 3-D surface plots were presented for graphi-
cal expression of the results.
2. Materials and methods
2.1. Materials
Microcrystalline cellulose (MCC) PH 101 (Balaji Drugs, Surat,
India); spray dried lactose (Signet Chemicals, Mumbai, India);
camphor (Su-lab Chemicals, Mumbai, India); crosscarmellose
sodium (Yarrow Chem. Products, Mumbai, India) were pur-
chased in present study. Telmisartan was received as a gift
sample from Vapi Care Pvt. Ltd. (Vapi, India). All reagents
were used of analytical grade and were used as received.
2.2. Methods
2.2.1. Preformulation studies
2.2.1.1. Flow property and compressibility of drug. Flow prop-
erty and compressibility of telmisartan were established by
determining parameters like Hausner’s ratio, Carr’s index
and angle of repose (United States Pharmacopoeial
Convention, 2008).2.2.1.2. Drug excipient compatibility studies. 2.2.1.2.1. Fourier
transform infrared spectroscopy (FT-IR). Chemical interaction
between drug and selected excipients was checked using FTIR
studies (Bruker Optics Alpha, Germany). IR spectra of
individual sample of telmisartan, MCC PH101 and CCS;
and physical mixture of drug with MCC PH 101 and drug with
CCS were recorded in the range of 4000–500 cm1.
2.2.1.2.2. Differential scanning calorimetry (DSC). Pure
drug and physical mixture of drug with MCC were subjected
to DSC study. 10 mg sample was heated in an aluminium
pan under nitrogen (50 mL/min) at 10 C/min from 30 to
300 C (Mettler-Toledo STARSW 9.20, USA). An empty
aluminium pan was used as a reference.
2.2.2. Formulation of immediate release pellets (preliminary
batches)
Three batches of placebo MCC pellets were prepared for
screening of ratio of ethanol to water (40:60, 50:50 and
60:40) as granulating ﬂuid. Pellets were successfully extruded
and spheronized and there was no signiﬁcant difference in %
morphology, yield and pellet size of pellets of the three
batches. Therefore, 60% ethanol and 40% water was selected
(as granulating liquid) for further studies. Higher concentra-
tion of ethanol would help for dissolution rate enhancement
of drug in further studies.
Five batches of placebo MCC pellets having 10%, 15%,
20%, 25% and 50% of lactose were tried but pellets were
not produced in batch with 25% and 50% of lactose due to
insufﬁcient plasticity of wet mass. Thus, 20% of spray dried
lactose was incorporated for further studies. Higher amount
of spray dried lactose would help in dissolution rate enhance-
ment of drug in further studies.
2.2.2.1. Formulation of immediate release pellets (preliminary
batches P1–P4). The required quantities of drug and excipients
were weighed according to the batch composition (Table 1)
and mixed for 10 min. The dry mixture was moistened with
ethanol: water mixture (60:40). The wet mass, thus formed,
was extruded through screen with perforations 1 mm in diame-
ter and 1.5 mm in thickness. The extrudates were subjected to
spheronization at 700 rpm until spherical pellets were obtained
(Cronimach, India). The resulting pellets were dried to con-
stant weight at 50 C and evaluated for morphology, ﬂow
property, compressibility, particle size analysis, % porosity,
drug content, and in vitro drug release.
2.2.3. Formulation of pellets prepared using 32 full factorial
design
Quantity of drug, MCC and other excipients was selected as
per 32 full factorial design. Concentrations of camphor and
Modiﬁed MCC pellets 581CCS were varied at three different levels (Table 2) (Vangala
et al., 2014; Putta et al., 2012).
Experiments were conducted using all 9 possible combina-
tions (Table 3). Pellets were prepared in a similar manner as
of preliminary batches and evaluated for the same set of
parameters.
2.2.4. Evaluation of pellets
2.2.4.1. Morphological characterization of pellets. The pellet
shape and surface morphology were observed by optical
microscope. Mean particle size and particle size distribution
were estimated by sieving method which directly gives weight
distribution. Sieves were arranged in a nest with the coarsest
at the top. 50 g sample was placed on the top sieve and sub-
jected to mechanical agitation for 10 min. The pellets retained
on each sieve were weighed. The pellets were assigned the mesh
number of the screen through which it passed to consider
undersize. It was expressed in terms of arithmetic mean of
the two sieves (Rashid, 2001). Mean particle size was
calculated using formula given in Eq. (1).
Mean particle size ¼ RXiFi
RFi
ð1Þ
RXiFi=Weight size.
RFi = Percentage weight retained.
2.2.4.2. Flow property, compressibility and % porosity.
Percentage porosity of pellets was determined by liquid dis-
placement method (Subrahmanyam, 2002). Flow property
and compressibility of telmisartan pellets were established by
determining parameters like Hausner’s ratio, Carr’s index
and angle of repose (United States Pharmacopoeial
Convention, 2008).
2.2.4.3. Drug content. Pellets were crushed and powder equiva-
lent to the 20 mg of drug was dissolved in 50 ml of methanol. It
was sonicated for 20 min. The volume was adjusted up to mark
with methanol. The solution was ﬁltered through Whatmann
ﬁlter paper and absorbance was recorded at 296 nm after suit-
able dilution. Percentage drug content was calculated using
calibration curve of drug prepared previously.
2.2.4.4. In vitro drug release study. Pellets equivalent to 20 mg
of telmisartan were used for the in vitro dissolution studies.
Dissolution was performed in 900 ml 0.1 N HCl using USP
dissolution apparatus I equipped with a basket operating atTable 2 Coding of the actual values for 32 full factorial
design.
Factors (Independent variables) Levels used
Low (1)
(%)
Medium (0)
(%)
High (+1)
(%)
X1 = percentage of camphor 2 6 10
X2 = percentage of cross
carmellose sodium
4 8 12
Dependent variables: Y1 =% porosity; Y2 =% drug release at
60 min.the speed of 100 rpm. Temperature of dissolution medium
was maintained at 37 ± 0.5 C. The amount of drug released
was measured at suitable time intervals using UV spectropho-
tometer (UV-3092, Lab India, India).
2.2.5. Statistical analysis
Various response surface methodology (RSM) computations
were performed using Design Expert 9.0.2 software (Trial ver-
sion). Polynomial models, including interactions and quadratic
terms, were generated for all the response variables of using
multiple linear regression analysis. In order to assess the relia-
bility of the developed mathematical model, three formula-
tions corresponding to random compositions covering entire
range of experimental domain were prepared and referred as
check-point batches. For each of these formulations, the
responses were estimated by the use of generated mathematical
models and by the experimental procedures. The linear
correlation plots between observed and predicted values of
the response properties were plotted using MS Excel 2010.
The % Error in prognosis (%PE) was calculated using Eq. (2):
%Error ¼ ðExperimental value predicted valueÞ
Experimental value
 100 ð2Þ2.2.6. SEM study
The size, shape and surface characteristics of pellets of opti-
mized batch were determined by scanning electron microscopy.
Aspect ratio and roundness of pellets were determined using
image analysis software (Image J).
2.2.7. Stability studies
Samples of the optimized batch were kept at 40 C/75% RH
and at room temperature for three months in high-density
polyethylene (HDPE) bottle. They were analysed for physical
characteristics, drug content, disintegration and in vitro drug
release at regular interval of 1 month till 3 months (ICH
Guideline, 2013).3. Results and discussion
3.1. Preformulation studies
3.1.1. Flow property and compressibility of drug
Carr’s index, Hausner’s ratio and angle of repose of drug pow-
der were 43.24%, 1.761 and 43, respectively which indicated
poor ﬂow and compressibility of drug.
3.1.2. Drug excipient compatibility studies
3.1.2.1. Differential scanning calorimetry (DSC). A strong
endothermic peak, observed at 78 C, was indicative of tem-
perature-induced phase transition and melting of telmisartan.
Phase transition started at 267 C and ended at 272 C
(Fig. 1(a)). Endotherm of drug was well-preserved in its physi-
cal mixture with MCC PH 101 (Fig. 1(b)) which shows no
incompatibility between MCC and telmisartan.
3.1.2.2. Fourier transform infrared spectroscopic (FT-IR)
analysis. IR spectra of telmisartan showed a characteristic
peak at 740 and 757 cm1 (ring vibration due to 1, 2-disubsti-
tuted benzene), 1350–1000 cm1 (CAN stretching vibrations),
Figure 1 DSC thermogram of: (a) telmisartan, (b) telmisartan +MCC, and (c) telmisartan + optimized formulation.
Table 3 Composition of factorial batches (F1–F9).
Batch Telmisartan (mg) MCC:Lactose Camphor (%) CCS (%) Ethanol:Water
F1 20 80:20 2 4 60:40
F2 20 80:20 2 8 60:40
F3 20 80:20 2 12 60:40
F4 20 80:20 6 4 60:40
F5 20 80:20 6 8 60:40
F6 20 80:20 6 12 60:40
F7 20 80:20 10 4 60:40
F8 20 80:20 10 8 60:40
F9 20 80:20 10 12 60:40
582 H. Patel et al.1455 and 1381 cm1 (CH3 bending vibrations), 1599 cm
1
(CAC aromatic band and stretching), 1460 cm1 (CAH bend)
and 1695 cm1 (C‚O stretching vibrations). Characteristic
peaks of telmisartan seemed to be preserved in both physical
mixtures (drug with MCC and drug with CCS) which proved
no chemical interaction of telmisartan with MCC and CCS
(Figs. 2 and 3).3.2. Evaluation of immediate release pellets (preliminary batches
P1–P4)
Spherical pellets having smooth surface were observed in opti-
cal microscope. Mean pellet size for all batches were observed
to be in the range of 927–954 lm. Percentage porosity of batch
P1, P2, P3 and P4 was 12.01%, 12.60%, 31.54% and 15.56%,
Figure 2 IR spectra of: (a) telmisartan, (b) MCC, and (c) physical mixture of telmisartan and MCC.
Modiﬁed MCC pellets 583respectively. There was no signiﬁcant difference in % porosity
of pellets of batches P2 and P4 with respect to P1 (p> 0.005).
Pellets of batch P3 exhibited maximum (31.54%) porosity
which could be due to the presence of camphor in the
formulation.
In vitro drug release of batch P1–P4 is displayed in Fig. 4.
Only 38.54% drug was released at 60 min in case of pellets pre-
pared with MCC alone. Drug release rate exhibited the follow-
ing order: MCC+ camphor >MCC+ CCS >MCC
+ spray dried lactose >MCC. Hence, it was considered
worthwhile to investigate the effect of incorporation of CCS,
camphor and MCC into the pellets using factorial design.
3.3. Evaluation of pellets prepared using 32 full factorial design
The results of percentage yield, bulk density, tapped density;
Hausner’s ratio, Carr’s index and angle of repose of pellets
are given in Table 4. Values of Hausner’s ratio, Carr’s index
and angle of repose were suggestive of excellent ﬂow properties
and compressibility of pellets of all batches. Average pellet size
remained within acceptable range. Thus, incorporation of
CCS, SDL and camphor to the MCC pellets did not deterio-
rate any of these characteristics appreciably.
The results of % porosity and % drug content are provided
in Table 5 and % drug release is displayed in Fig. 5. More than
80% of drug was released at 60 min in batches F5–F9. As theconcentration of camphor and CCS was increased, % porosity
and % drug release was increased. It corroborates to the ﬁnd-
ings of Benchawan and Pornsak (2013) who reported improve-
ment in dissolution and disintegration behaviour of MCC
pellets through inclusion of polyethylene glycol, polysorbate
and crosscarmellose sodium. In our case, desired results were
obtained in batch F9 which contained the highest concentra-
tion of camphor and CCS. Percentage drug release of batch
F9 was signiﬁcantly higher compared to preliminary batches
P3 and P4. Souto C (Souto et al., 2013) and co-workers studied
the effect of crosscarmellose sodium and sodium starch glyco-
late for increasing the dissolution rate of pellets containing
hydrochlorothiazide. However, only slight increment in drug
release was observed. Water wicking and swelling are the
two possible mechanisms of disintegrant action. The exposure
to water causes ingredients to swell and exerts pressure against
surrounding of formulation ingredients, which, in turn, results
into disintegration of the formulation. Tablets prepared with
camphor exhibited rapid disintegration due to an improvement
in the ability of water to penetrate into the tablets subsequent
to generation of high porosity after sublimation of camphor
(Oh et al., 2013; Keiichi et al., 1997). We attributed the
improvement drug release characteristics of our formulation
to the synergistic effect of camphor and CCS. Bhardwaj
et al. (2010) reported this fact for fast dissolving tablet dosage
form.
Figure 3 IR spectra of: (a) telmisartan, (b) CCS, and (c) physical mixture of telmisartan and CCS.
Figure 4 In vitro drug release of preliminary batches (P1–P4).
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Results of Y1 and Y2 for all batches (F1–F9) showed a wide
variation; which indicated that the values of dependent vari-
ables were strongly dependent on the independent variables.
There was not much difference between the actual and pre-
dicted values of Y1 and Y2 which indicated good predictability
of the selected model. Responses observed for each of the
formulations (F1–F9) were simultaneously ﬁtted to quadratic
model using Design Expert 9.0.2.3.4.1. Data analysis of Y1 (% Porosity)
Y1 ¼ 22:5156þ 6:8100X1 þ 1:90333X2 þ 01:38750X1X2
þ 0:12667X21  0:3333X22 ð3Þ
The observed value for % porosity for all 9 batches (F1–F9)
varied from 15.01% to 32.33% among the batches.
Correlation coefﬁcient was found to be 0.9904 which showed
best ﬁt to the model. Positive sign of X1 and X2 in regression
equation (3) indicated agonistic effect of independent variables
on response. Out of two independent variables, X1 had higher
value of co-efﬁcient (6.81) compared to X2 (1.90) which indi-
cated that X1 had prominent effect on Y1.
3.4.2. Data analysis of Y2 (%drug release at 60 min)
Y2 ¼ þ81:3033þ 16:360X1 þ 6:908X2  6:515X1X2
 3:360X21 þ 0:495X22 ð4Þ
The observed value for % drug release at 60 min varied
from 47.19% to 96.95%. The value of correlation coefﬁcient
was found to be 0.9885 which showed best ﬁt to the model.
Positive sign of X1, and X2 in regression equation (4) indicated
agonistic effect of independent variables on response. X1 with
higher value of co-efﬁcient (16.36 as against to 6.903 with X2)
showed much pronounced effect upon Y2.
Table 4 Results of ﬂow properties and particle size of pellets of batches F1–F9.
Batches %
Yield
Bulk densitya (gm/
cm3)
Tapped densitya (gm/
cm3)
Carr0s index
(%)
Hausner’s
ratio
Angle of repose
()a
Avg. particle size
(lm)
F1 83.64 0.701 ± 0.023 0.723 ± 0.045 1.98 1.03 18.43 ± 1.25 950.06
F2 88.24 0.817 ± 0.019 0.825 ± 0.068 1.01 1.01 18.26 ± 2.35 955.84
F3 86.32 0.649 ± 0.026 0.656 ± 0.48 1.02 1.01 18.72 ± 3.15 948.07
F4 81.42 0.656 ± 0.098 0.67 ± 0.015 2.04 1.02 16.47 ± 1.87 935.67
F5 81.67 0.618 ± 0.064 0.625 ± 0.027 1.02 1.01 18.14 ± 1.54 940.45
F6 86.9 0.670 ± 0.078 0.698 ± 0.059 3.99 1.04 18.26 ± 3.25 947.72
F7 71.99 0.798 ± 0.098 0.831 ± 0.014 3.99 1.04 18.43 ± 1.53 948.88
F8 83.56 0.659 ± 0.056 0.68 ± 0.049 3 1.03 19.87 ± 1.49 991.42
F9 89.44 0.701 ± 0.065 0.716 ± 0.020 1.99 1.02 18.43 ± 1.66 913.50
a Mean (n= 3) ± SD.
Table 5 % Porosity and % drug content of batches (F1–F9).
Batches % Porositya (n= 3) % Drug contenta (n= 20)
F1 15.01 ± 2.05 86.71 ± 1.69
F2 15.13 ± 1.05 88.25 ± 2.56
F3 16.69 ± 1.45 82 ± 1.98
F4 20.98 ± 1.98 83.98 ± 3.56
F5 22.49 ± 2.45 90.2 ± 2.05
F6 23.49 ± 1.98 76.55 ± 2.06
F7 25.1 ± 1.58 87.1 ± 3.45
F8 30.26 ± 2.36 80.86 ± 2.15
F9 32.33 ± 1.69 79.29 ± 2.27
a Mean ± SD.
Figure 5 In vitro drug release of factorial batches (F1–F9).
Modiﬁed MCC pellets 5853.4.3. Contour plots, 3D-response surface plots and validation of
response surface methodology
The response surface and contour plots are the graphical
representation of the regression equation used to visualize
the relationship between the response and experimental levels
of each factor. 2-D contour plots and 3-D surface plots were
drawn using the design expert 9.0.2 software (Fig. 6). Non-
linear relationship was observed between two factors with
two responses (% porosity and % drug release at 60 min).Pellet composition of the check-point batches, their
predicted values and experimental values of all the response
variables, and % Error is mentioned in Table 6. There was
not much difference between actual and predicted value which
indicated reliability of the optimization procedure.
3.5. Formulation and evaluation of optimized batch
Based on the inferences derived from Design Expert, optimized
formulation (Batch F10) consisted of 9.248% Camphor, 12%
CCS, MCC to spray dried lactose ratio of 80:20 and mixture
of ethanol–water (60:40) as granulating liquid was prepared
and evaluated. The desirable ranges of responses were
restricted to maximum porosity and 100% drug release in
design expert software. The target range of these responses
was restricted to a stricter range than the USP speciﬁcation,
considering the dissolution proﬁles of the commercial product.
Considering the values of Hausner’s ratio (1.01) and Carr’s
index (1.28), optimized batch showed excellent ﬂow property
and compressibility. Average particle size and drug content
of pellets were in acceptable range. In DSC study, no shifting
of melting endotherm of drug was conclusive of no incompati-
bility of drug with any of the excipients (Fig. 1). Though,
intensity of the melting peak was reduced which could possibly
be due to dilution effect exerted by the excipients. Percentage
porosity and percentage drug release of batch F10 were 29.98
and 94.25, respectively. There was not much difference
between observed and predicted response for the optimized
batch. Keeping in view aforementioned ﬁndings, batch F10,
was successfully developed to improve dissolution rate of
telmisartan from MCC pellets.
3.6. SEM study
SEM photomicrograph (Fig. 7) showed that the pellets were
spherical in nature and had a smooth surface. From the pho-
tomicrograph image analysis, calculated Aspect Ratio (AR)
and Roundness of pellets were found to be 1.006 ± 0.0005
and 0.9812 ± 0.0041, respectively. The obtained AR and
roundness of the pellets were closer to the value of 1, which
conﬁrmed that the prepared pellets were spherical in nature
(Gupta et al., 2011).
Figure 6 Contour plots and 3D response surface plots for responses (a) Y1 and (b) Y2.
Table 6 Composition of checkpoint formulations, the pre-
dicted and experimental values of response variables and
percentage error.
Checkpoint
batches
composition
(X1:X2)
Response
variables
Experimental
value
Predicted
value
%
Error
0.5:0.5 % Porosity (Y1)
% Drug release at
60 min (Y2)
28.52
92.35
27.17
90.57
4.73
1.92
0.5:0.5 % Porosity (Y1)
% Drug release at
60 min (Y2)
17.79
65.38
18.54
67.32
4.21
2.96
0.5:0.5 % Porosity (Y1)
% Drug release at
60 min (Y2)
23.06
84.25
24.57
86.94
5.16
3.19
Figure 7 SEM image of pellets of the optimized batch (F10).
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No signiﬁcant changes were observed in appearance, Carr’s
index, Hausner’s ratio, average pellets size, drug content and
in vitro drug release of optimized pellets at room temperature
and at accelerated condition of 40 C/75% RH for 3 months,
indicating stability of batch F10.4. Conclusion
In the present research work, novel formulations of MCC pel-
lets with faster drug release were successfully developed. The
optimized batch (F10) consisted of 9.248% Camphor, 12%
CCS, MCC to spray dried lactose ratio of 80:20 and mixture
of ethanol–water (60:40) as granulating liquid. Independent
variables, concentration of camphor (X1) and concentration
of CCS (X2), exhibited a positive effect upon % porosity
(Y1) and percentage drug release at 60 min (Y2). As per
Modiﬁed MCC pellets 587co-efﬁcient of factorial design, camphor had prominent effect
on percentage drug release and percentage porosity.
Combination of camphor and CCS into MCC pellets exhibited
synergistic effect on responses. Such an approach can be
exploited for improving the dissolution rate of other poorly
water soluble drugs.
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